These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 36853472)
1. Role of P11 through serotonergic and glutamatergic pathways in LID. Noori A; Farhadi K; Mohtasham Kia Y; Hosseini N; Mehrabi S Mol Biol Rep; 2023 May; 50(5):4535-4549. PubMed ID: 36853472 [TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Fox SH; Chuang R; Brotchie JM Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047 [TBL] [Abstract][Full Text] [Related]
3. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. Sebastianutto I; Cenci MA Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424 [TBL] [Abstract][Full Text] [Related]
4. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease. Morin N; Di Paolo T Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965 [TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747 [TBL] [Abstract][Full Text] [Related]
6. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709 [TBL] [Abstract][Full Text] [Related]
7. New insights into pathogenesis of l-DOPA-induced dyskinesia. Zheng C; Zhang F Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976 [TBL] [Abstract][Full Text] [Related]
8. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956 [TBL] [Abstract][Full Text] [Related]
9. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease. Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045 [TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168 [TBL] [Abstract][Full Text] [Related]
11. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Iderberg H; Rylander D; Bimpisidis Z; Cenci MA Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003 [TBL] [Abstract][Full Text] [Related]
12. Nitric oxide, a new player in L-DOPA-induced dyskinesia? Del-Bel E; Padovan-Neto FE; Bortolanza M; Tumas V; Aguiar AS; Raisman-Vozari R; Prediger RD Front Biosci (Elite Ed); 2015 Jan; 7(1):168-92. PubMed ID: 25553372 [TBL] [Abstract][Full Text] [Related]
13. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574 [TBL] [Abstract][Full Text] [Related]
14. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model. Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244 [TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for levodopa-induced dyskinesia. Al Dakheel A; Beaulieu-Boire I; Fox SH Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568 [TBL] [Abstract][Full Text] [Related]
16. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Ko WK; Li Q; Bezard E Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of l-DOPA-induced dyskinesia. Fisone G; Bezard E Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084 [TBL] [Abstract][Full Text] [Related]
18. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492 [TBL] [Abstract][Full Text] [Related]